Fanconi syndrome is very uncommon in hepatitis B virus infected patients treated with tenofovir. Proximal tubular cells of kidney are particularly sensitive to the toxic effects of tenofovir due to their unique set of cell membrane transporters that favour entry of the drug. A 47-year old male with hepatitis-B virus (HBV) infection presented with sudden onset of weakness of all four limbs, difficulty in walking, myalgia and slurring of speech, polyuriasince past two days. Twelve months before admission, the patient had been initiated on tenofovir 300 mg as treatment for HBV infection.Fanconi syndrome (FS) was diagnosed based on normal anion gap acidosis with hypokalemia, hypophosphatemia, glucosuria, aminoaciduria (Amino acid presence in urine- very high), and proteinuria. This case and the other cases reported to date suggest thattenofovir causes Fanconi syndrome, and that this may become more problematic with more widespread use of the drug. The possibility of irreversible renal damage also suggests that patients given this drug should be followed more closely in the 12- to 18-month period after initiation of tenofovir therapy and should have a urinalysis, serum creatinine, and potassium performed on a regular basis following initiation of therapy. Raising the awareness of clinicians with regard to the potential for this side effect is important so that patients with this side effect can be discovered early and switched to an alternate antiviral therapy.
|Number of pages||4|
|Journal||Research Journal of Pharmaceutical, Biological and Chemical Sciences|
|Publication status||Published - 2014|
All Science Journal Classification (ASJC) codes
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)